Related Experiment Video

Updated: May 24, 2026

A Simple, Rapid, and Quantitative Assay to Measure Repair of DNA-protein Crosslinks on Plasmids Transfected into Mammalian Cells
11:58

A Simple, Rapid, and Quantitative Assay to Measure Repair of DNA-protein Crosslinks on Plasmids Transfected into Mammalian Cells

Published on: March 5, 2018

DNA interstrand cross-linking agents and their chemotherapeutic potential

L Brulikova1, J Hlavac, P Hradil

  • 1Institute of Molecular and Translational Medicine, Department of Organic Chemistry, Faculty of Science, Palacky University, 17. listopadu 12, 771 46 Olomouc, Czech Republic.

Current Medicinal Chemistry
|February 17, 2012
PubMed

Insights

DNA interstrand cross-linking agents are cytotoxic drugs that halt cancer cell division. Understanding their formation and repair mechanisms is key to developing effective anticancer therapies and overcoming drug resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • DNA interstrand cross-linking (ICL) agents are cytotoxic drugs that bind DNA, inhibiting replication and transcription.
  • Their therapeutic potential in anticancer therapy is often limited by cellular resistance mechanisms.
  • Studying ICL agent efficacy and repair pathways is crucial for developing novel antitumor strategies.

Purpose of the Study:

  • To review the development and application of DNA interstrand cross-linking agents over the past decade.
  • To discuss their potential as anticancer chemotherapeutics in light of current knowledge.
  • To explore the role of repair mechanisms and combined chemotherapy strategies.

Main Methods:

  • Literature review of recent advancements in DNA interstrand cross-linking agents.
  • Analysis of established and emerging ICL agents.
  • Discussion of drug resistance and repair mechanisms.
  • Exploration of combined chemotherapy approaches.

Main Results:

  • Overview of well-known and novel DNA interstrand cross-linking agents.
  • Insights into mechanisms of drug resistance.
  • Understanding of DNA repair pathways relevant to ICL agents.
  • Discussion on the potential of combined chemotherapy strategies.

Conclusions:

  • Continued research into DNA interstrand cross-linking agents is vital for advancing cancer therapy.
  • Targeting repair mechanisms and employing combination therapies can enhance the efficacy of ICL agents.
  • Developing new ICL agents with improved efficacy and reduced resistance is a key goal.

More Related Videos

Tools to Study the Role of Architectural Protein HMGB1 in the Processing of Helix Distorting, Site-specific DNA Interstrand Crosslinks12:19

Tools to Study the Role of Architectural Protein HMGB1 in the Processing of Helix Distorting, Site-specific DNA Interstrand Crosslinks

Published on: November 10, 2016

Visualization of DNA Repair Proteins Interaction by Immunofluorescence07:55

Visualization of DNA Repair Proteins Interaction by Immunofluorescence

Published on: June 26, 2020

Related Concept Videos

Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
Fixing Double-strand Breaks02:04

Fixing Double-strand Breaks

The double-stranded structure of DNA has two major advantages. First, it serves as a safe repository of genetic information where one strand serves as the back-up in case the other strand is damaged. Second, the double-helical structure can be wrapped around proteins called histones to form nucleosomes, which can then be tightly wound to form chromosomes. This way, DNA chains up to 2 inches long can be contained within microscopic structures in a cell. A double-stranded break not only damages...
Fixing Double-strand Breaks02:04

Fixing Double-strand Breaks

The double-stranded structure of DNA has two major advantages. First, it serves as a safe repository of genetic information where one strand serves as the back-up in case the other strand is damaged. Second, the double-helical structure can be wrapped around proteins called histones to form nucleosomes, which can then be tightly wound to form chromosomes. This way, DNA chains up to 2 inches long can be contained within microscopic structures in a cell. A double-stranded break not only damages...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...